Oxford Immunotec's T-SPOT®.TB Test Included in the World Health Organization's First-Ever Essential Diagnostics List
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 21, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that the Company's T-SPOT.TB test for tuberculosis (TB) infection has been included in the World Health Organization (WHO) Model List of Essential In Vitro Diagnostics (EDL) - First Edition.
The EDL includes the 113 most important tests recommended by WHO for use at various levels of the health care system. These essential diagnostics satisfy the priority health care needs of the population and were selected with due regard to disease prevalence and public health relevance, evidence of efficacy and accuracy, and comparative cost-effectiveness. 58 of the tests listed are for the detection and diagnosis of a wide range of common conditions, providing an essential package that can form the basis for screening and management of patients. The remaining 55 tests are designed for the detection, diagnosis, and monitoring of WHO key disease areas, for which there is high quality evidence - HIV, tuberculosis (TB), malaria, hepatitis B and C, syphilis and human papilloma virus. Included in the list were interferon-gamma release assays, of which Oxford Immunotec's T-SPOT.TB test is one of two available globally.
"Despite steady progress in reducing the burden of tuberculosis in recent decades, TB remains a major global health problem and one of the top 10 causes of death worldwide," said Dr. Richard Wenstrup, Chief Medical Officer of Oxford Immunotec. "As acknowledged in the February 2018 publication of new WHO guidelines1, the identification and management of LTBI in people with a high risk of developing active TB is a critical component of the WHO End TB Strategy. We applaud the inclusion of IGRAs in the WHO's EDL and are pleased to see further recognition of the important role IGRAs will play in the global fight against TB."
1 Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, and intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For Media and Investor Inquiries:
Head of Strategy and Investor Relations
Tel: +1 (508) 556-1377
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Result of Riksbank certificate sale17.9.2019 10:15:00 CEST | Press release
CERTIFICATE MATURITY 190925 FIXED RATE -0.25 % OFFERED VOLUME 418.600 BLN TOTAL BID AMOUNT 390.100 BLN ACCEPTED VOLUME 390.100 BLN PERCENTAGE ALLOTTED 100.0000 % NUMBER OF BIDS 9 DEPOSIT RATE -1.00 % LENDING RATE 0.50 %
Ahold Delhaize share buyback update17.9.2019 09:56:00 CEST | Press release
Zaandam, the Netherlands, September 17, 2019 – Ahold Delhaize has repurchased 271,700 of Ahold Delhaize common shares in the period from September 9, 2019 up to and including September 13, 2019. The shares were repurchased at an average price of €22.32 per share for a total consideration of €6.1 million. These repurchases were made as part of the €1 billion share buyback program announced on November 13, 2018. The total number of shares repurchased under this program to date is 35,384,387 common shares for a total consideration of €762.9 million. Download the share buyback transactions excel sheet for detailed individual transaction information from www.aholddelhaize.com/en/investors/share-information/share-buy-back-programs/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.
Conditions for sale of Riksbank certificates17.9.2019 09:30:00 CEST | Press release
AUCTION DATE: SEP 17, 2019 START DATE: SEP 18, 2019 MATURITY DATE: SEP 25, 2019 NOMINAL AMOUNT: 418.6 BLN FIXED RATE: -0.25 % ALL MONETARY POLICY COUNTERPARTIES ARE INVITED TO SUBMIT BIDS TO THE RIKSBANK (08-6966970) BY 10.00 AM ON SEP 17 2019, AT THE LATEST. CONFIRMATION OF BIDS TO E-MAIL: RBCERT@riksbank.se THE LOWEST ACCEPTED BID VOLUME IS SEK 1 MLN. THE HIGHEST ACCEPTED BID VOLUME IS SEK 418.6 BLN. RESULT OF AUCTION WILL BE PUBLISHED AT 10.15 (CEST) ON SEP 17, 2019. COMPLETE TERMS AND CONDITIONS CAN BE RETRIEVED AT WWW.RIKSBANK.SE
Medtronic Introduces Envision™ Pro Continuous Glucose Monitoring (CGM) System in Europe17.9.2019 09:00:00 CEST | Press release
Next-Generation Professional CGM Combines Valuable Data with Optimal User Experience DUBLIN, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, today announced the Envision™ Pro Continuous Glucose Monitoring (CGM) system — a fully disposable, zero calibration professional CGM system — has obtained CE (Conformité Européenne) Mark approval. Medtronic will begin commercial release in Europe and the Middle East this fall, subject to local regulatory requirements1. This new technology will empower healthcare professionals and their patients with either type 1 and type 2 diabetes to see accurate glucose levels and trends over time to develop more optimal diabetes therapy plans. "Medtronic has a 20-year history in professional CGM as the first company to have an approved physician-use CGM system," said Sheri Dodd, vice president and general manager for the Non-Intensive Diabetes Therapies business at Medtronic. "The la
Vestas receives 34 MW order in Norway with 27-year service agreement17.9.2019 09:00:00 CEST | Press release
News release from Vestas Northern and Central Europe Hamburg, 17 September 2019 Vestas has received a 34 MW order for the Haramsfjellet wind project on the island of Haramsøya in western Norway. Vestas has developed a solution to fit the site’s wind conditions that includes eight V136-4.2 MW turbines and a long-term service contract to optimise energy production for the lifetime of the project in a high wind location. With a robust design for tough wind sites, the turbine is well-suited for the challenging climatic conditions that are commonly found on Norway’s western coastline. The order is placed by Finnish-based Taaleri Energia investing via their SolarWind II fund in the project that will have an annual production of about 112 GWh; enough electricity to supply around 7,000 Norwegian households. “After 21 years of development of the Haram wind farm project we are delighted to finally build the project. Great cooperation with Taaleri, Vestas and other suppliers, consultants and loca
Prosafe SE: Update on Merger process with Floatel – Competition Process UK17.9.2019 08:18:00 CEST | Press release
Reference is made to press release published on 5th September. Prosafe has been informed by the Competition and Markets Authority (CMA) in the UK that they will refer the merger to Phase 2. Prosafe confirms that the company will apply for a three-week extension in order to evaluate whether to enter Phase 2. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 17 September 2019 Prosafe SE For further information, please contact: Glen Ole Rødland, Chairman of Prosafe: + 47 907 41 662 Jesper Kragh Andresen, CEO of Prosafe: +47 907 65 155 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act